SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fernö Mårten) "

Sökning: WFRF:(Fernö Mårten)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Carlsson, Michael, et al. (författare)
  • Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease.
  • 2012
  • Ingår i: Biochimica et biophysica acta. - Elsevier. - 0006-3002. ; 1820:9, s. 1366-1372
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Changes in glycosylation of serum proteins are common, and various glycoforms are being explored as biomarkers in cancer and inflammation. We recently showed that glycoforms detected by endogenous galectins not only provide potential biomarkers, but also have different functions when they encounter galectins in tissue cells. Now we have explored the use of a combination of two galectins with different specificities, to further increase biomarker sensitivity and specificity. METHODS: Sera from 14 women with metastatic breast cancer, 12 healthy controls, 14 patients with IgA-nephritis (IgAN), and 12 patients with other glomerulonephritis were fractionated by affinity chromatography on immobilized human galectin-1 or galectin-8N, and the protein amounts of the bound and unbound fractions for each galectin were determined. RESULTS: Each galectin bound largely different fractions of the serum glycoproteins, including different glycoforms of haptoglobin. In the cancer sera, the level of galectin-1 bound glycoproteins was higher and galectin-8N bound glycoproteins lower compared to the other patients groups, whereas in IgAN sera the level of galectin-8N bound glycoproteins were higher. CONCLUSION: The ratio of galectin-1 bound/galectin-8N bound glycoproteins showed high discriminatory power between cancer patients and healthy, with AUC of 0.98 in ROC analysis, and thus provides an interesting novel cancer biomarker candidate. GENERAL SIGNIFICANCE: The galectin-binding ability of a glycoprotein is not only a promising biomarker candidate but may also have a specific function when the glycoprotein encounters the galectin in tissue cells, and thus be related to the pathophysiological state of the patient. This article is part of a Special Issue entitled Glycoproteomics.
  •  
2.
  • Aaltonen, Kristina, et al. (författare)
  • Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.
  • 2014
  • Ingår i: BMC Cancer. - BioMed Central (BMC). - 1471-2407. ; 14
  • Tidskriftsartikel (refereegranskat)abstract
    • Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.
3.
  •  
4.
  •  
5.
  • Alkner, Sara, et al. (författare)
  • AIB1 is a predictive factor for tamoxifen response in premenopausal women.
  • 2010
  • Ingår i: Annals of Oncology. - Oxford University Press. - 1569-8041. ; 21, s. 238-244
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry. RESULTS: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm, high AIB1 was a negative prognostic factor for recurrence-free survival (RFS) (P = 0.02). However, ER-positive patients with high AIB1 responded significantly to tamoxifen treatment (P = 0.002), increasing RFS to the same level as for systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS from the beginning, this was not further improved by tamoxifen (P = 0.8). CONCLUSIONS: In the control group, high AIB1 was a negative prognostic factor. However, ER-positive patients with high AIB1 responded significantly to tamoxifen. This implicates high AIB1 to be an independent predictive factor of improved response to tamoxifen and not, as has previously been discussed, a factor predicting tamoxifen resistance.
  •  
6.
7.
  • Alkner, Sara, et al. (författare)
  • Prediction of outcome after diagnosis of metachronous contralateral breast cancer.
  • 2011
  • Ingår i: BMC Cancer. - BioMed Central (BMC). - 1471-2407. ; 11
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis. METHODS: Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints. RESULTS: The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS. CONCLUSIONS: In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings.
8.
  • Alkner, Sara, et al. (författare)
  • Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
  • 2016
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 11:3
  • Tidskriftsartikel (refereegranskat)abstract
    • The estrogen receptor coactivator Amplified in Breast Cancer 1 (AIB1) has been associated with an improved response to adjuvant tamoxifen in breast cancer, but also with endocrine treatment resistance. We hereby use metachronous contralateral breast cancer (CBC) developed despite prior adjuvant tamoxifen for the first tumor as an "in vivo"-model for tamoxifen resistance. AIB1-expression in the presumable resistant (CBC after prior tamoxifen) and naïve setting (CBC without prior tamoxifen) is compared and correlated to prognosis after CBC.
9.
10.
  • Alkner, Sara, et al. (författare)
  • Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
  • 2009
  • Ingår i: European Journal of Cancer. - Elsevier. - 1879-0852. ; 45, s. 2496-2502
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p=0.02). In subgroup analysis the risk reduction was most pronounced in patients <40 years of age (HR 0.09, p=0.02). A risk reduction was also seen in women 40-49 years of age or >/=50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. CONCLUSION: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women <40 years of age. The effect of tamoxifen was not significantly dependent on time.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (68)
Typ av publikation
tidskriftsartikel (197)
konferensbidrag (15)
doktorsavhandling (2)
annan publikation (1)
Typ av innehåll
refereegranskat (212)
övrigt vetenskapligt (21)
Författare/redaktör
Fernö, Mårten, (213)
Bendahl, Pär Ola, (82)
Baldetorp, Bo, (58)
Rydén, Lisa, (55)
Malmström, Per, (43)
Grabau, Dorthe, (34)
visa fler...
Olsson, Håkan, (31)
Borg, Åke, (30)
Lövgren, Kristina, (25)
Killander, Dick, (23)
Stål, Olle, (19)
Ferno, M, (18)
Jirström, Karin, (16)
Gruvberger, Sofia, (13)
Åkerman, Måns, (13)
Loman, Niklas, (13)
Landberg, Göran, (12)
HATSCHEK, T (12)
Hedenfalk, Ingrid, (11)
Ehinger, Anna, (11)
Alkner, Sara (11)
Ringnér, Markus, (11)
Idvall, Ingrid, (11)
Niméus, Emma, (10)
Bergh, J, (9)
Olsson, Hans (9)
Liedberg, Fredrik, (9)
Gudjonsson, Sigurdur ... (9)
Stal, O (9)
Bergh, Jonas (9)
Höglund, Mattias, (9)
Saal, Lao, (9)
Peterson, Carsten, (9)
Ingvar, Christian, (9)
Edén, Patrik, (8)
Bendahl, Po (8)
Rydholm, Anders, (8)
Anderson, Harald (8)
Månsson, Wiking, (8)
Sigurdsson, Helgi (8)
Fjällskog, Marie Lou ... (7)
Borrebaeck, Carl, (7)
Ringberg, Anita (7)
Sjödahl, Gottfrid, (7)
Nordenskjöld, Bo, (7)
Lindgren, David, (7)
Wingren, Christer, (7)
Loman, N (7)
Lauss, Martin, (7)
Malmstrom, P. (7)
visa färre...
Lärosäte
Lunds universitet (200)
Karolinska Institutet (17)
Göteborgs universitet (9)
Linköpings universitet (8)
Uppsala universitet (5)
Umeå universitet (2)
Språk
Engelska (210)
Svenska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (213)
Naturvetenskap (4)
Teknik (1)
Lantbruksvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy